A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan
← catalyst calendarNCT05228158 · readout in 590 d
Sponsored by Eisai Co., Ltd. (industry) · 4523.T — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
145estimated
Sites
135
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-08-16 | actual | When the study began enrolling |
| Primary completion | 2028-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2022-02-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lymphoma, Follicular
Intervention
- Drug: Tazemetostat — also filed as Tazverik
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Adverse Drug Reactions (ADRs)
measured Up to Week 52
Number of Participants With Serious ADRs
measured Up to Week 52
Permalink · 4523.T's whole pipeline · Catalyst calendar · Every registered study · What changed